XML 80 R54.htm IDEA: XBRL DOCUMENT v3.25.1
GOODWILL AND INTANGIBLE ASSETS (Tables)
 12 Months Ended
Dec. 31, 2024
Disclosure Of Goodwill And Intangible Assets [Abstract]  
Schedule of Goodwill and Intangible Assets
 
  
Goodwill
US$‘000
    
Development
costs
US$‘000
    
Patents and
licenses
US$‘000
    
Technology
based intangibles
US$‘000
    
Other
US$‘000
    
Total
US$‘000
  
Cost
                                    
At January 1, 2023
    
79,182
      
125,584
      
8,729
      
-
      
33,580
      
247,075
  
Additions
    
-
      
1,758
      
19
      
-
      
110
      
1,887
  
Disposals or retirements
    
(12,591
)
    
-
      
-
      
-
      
(14,488
)
    
(27,079
)
Reclassifications
    
54
      
-
      
(54
)
    
-
      
-
      
-
  
Exchange adjustments
    
-
      
23
      
-
      
-
      
-
      
23
  
 
                                                
At December 31, 2023
    
66,645
      
127,365
      
8,694
      
-
      
19,202
      
221,906
  
 
                                                
At January 1, 2024
    
66,645
      
127,365
      
8,694
      
-
      
19,202
      
221,906
  
Additions
    
-
      
8,582
      
1
      
-
      
2,280
      
10,863
  
Additions through acquisition
    
13,839
      
122
      
-
      
13,105
      
-
      
27,066
  
Disposals or retirements
    
-
      
(70
)
    
-
      
-
      
-
      
(70
)
 
                                                
At December 31, 2024
    
80,484
      
135,999
      
8,695
      
13,105
      
21,482
      
259,765
  
 
                                                
Accumulated amortisation and Impairment losses
                                                
At January 1, 2023
    
(66,645
)
    
(108,576
)
    
(8,570
)
    
-
      
(28,015
)
    
(211,806
)
Charge for the year (Note 9)
    
-
      
(753
)
    
30
      
-
      
(223
)
    
(946
)
Disposals or retirements
    
-
      
-
      
-
      
-
      
12,956
      
12,956
  
Impairment losses (Note 5)
    
-
      
(2,926
)
    
(9
)
    
-
      
(2,898
)
    
(5,833
)
Exchange adjustments
    
-
      
(7
)
    
-
      
-
      
-
      
(7
)
 
                                                
At December 31, 2023
    
(66,645
)
    
(112,262
)
    
(8,549
)
    
-
      
(18,180
)
    
(205,636
)
 
                                                
At January 1, 2024
    
(66,645
)
    
(112,262
)
    
(8,549
)
    
-
      
(18,180
)
    
(205,636
)
Charge for the year (Note 9)
    
-
      
(1,190
)
    
-
      
-
      
-
      
(1,190
)
Impairment losses (Note 5)
    
-
      
(1,596
)
    
-
      
-
      
-
      
(1,596
)
 
                                                
At December 31, 2024
    
(66,645
)
    
(115,048
)
    
(8,549
)
    
-
      
(18,180
)
    
(208,422
)
 
                                                
Carrying amounts
                                                
At December 31, 2024
    
13,839
      
20,951
      
146
      
13,105
      
3,302
      
51,343
  
 
                                                
At December 31, 2023
    
-
      
15,103
      
145
      
-
      
1,022
      
16,270
  
Schedule of Principal Development Projects
Product Name
  
2024
US$’000
    
2023
US$’000
  
Continuous glucose monitoring testing
    
7,040
      
-
  
Premier Instruments for A1c and haemoglobinopathies testing
    
1,542
      
1,669
  
Mid-tier haemoglobins instrument
    
-
      
51
  
HIV screening rapid test
    
-
      
6
  
Other projects
    
-
      
32
  
Total capitalised development costs
    
8,582
      
1,758
  
Schedule of Impairment Loss Recorded on Discontinued Assets
   
December 31, 2024
    
December 31, 2023
  
   
US$’000
    
US$’000
  
Immco Diagnostics Inc.
    
101
      
9,331
  
Trinity Biotech Manufacturing Limited
    
(120
)
    
1,500
  
Trinity Biotech Do Brasil
    
162
      
274
  
Primus Corp
    
916
      
-
  
Clark Laboratories Inc.
    
130
      
-
  
Biopool US Inc.
    
219
      
-
  
                 
Total impairment loss
    
1,408
      
11,105
  
Schedule of Impairment Loss for Each Class of Asset
 
  
December 31, 2024
    
December 31, 2023
  
   
US$’000
    
US$’000
  
Goodwill and other intangible assets
    
1,596
      
5,833
  
Property, plant and equipment (see Note 11)
    
612
      
3,772
  
Financial assets (see Note 13)
    
(800
)
    
1,500
  
                 
Total impairment loss
    
1,408
      
11,105
  
Schedule of Specific Asset Impairment Charges
Asset name
  
 
Entity
  
2024
US$’000
  
T10 HPLC Analyzer
  
Trinity Biotech Manufacturing Ltd
    
916
  
Syphilis Point-of-Care
  
Trinity Biotech Manufacturing Ltd
    
680
  
Trinscreen plant & equipment
  
Trinity Biotech Manufacturing Ltd
    
223
  
Kansas right-of-use asset
  
Primus Corp.
    
133
  
Total
        
1,952
  
Schedule of Significant Goodwill
Goodwill arising from the purchase of CGM assets from Waveform Technologies
 
     
December 31,
2024
  
Carrying amount of goodwill (US$’000)
      
12,403
  
Discount rate applied (real pre-tax)
    
18.6
 %
% EBITDA would need to decrease for an impairment to arise
      
56.51
%
Long-term growth rate
      
2.0
%
Goodwill arising from the acquisition of EpiCapture Limited
 
   
December 31,
2024
  
Carrying amount of goodwill (US$’000)
    
1,420
 
Discount rate applied (real pre-tax)
  
21.9
%
% EBITDA would need to decrease for an impairment to arise
    
84.35
%
Long-term growth rate
    
2.0
%
Schedule of Internal and External Factors Based on Historical Experience
Intangible Assets with Indefinite Useful lives
(included in other intangibles)
  
December 31, 2024
US$‘000
    
December 31, 2023
US$‘000
  
             
Primus Corporation CGU
            
Primus trade name
    
365
      
365
  
Total
    
365
      
365